Publications by authors named "Jan Bassali"
US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma.
Clinicoecon Outcomes Res
June 2020
Objective: To estimate the budgetary impact of adopting selinexor (XPOVIO; Karyopharm Therapeutics, Inc.) for the treatment of adult patients with penta-refractory multiple myeloma (MM) from the perspective of a third-party payer in the United States (US).
Methods: A budget impact analysis was conducted in one-year increments for the first 3 years after the introduction of selinexor for a private payer or Medicare Part D.